AgomAb Therapeutics

Biotech · Ghent, BE

Biotech developing therapies targeting fibrosis and Crohn's disease.

Founders

Paolo Michieli (Italy · ♂) — His two-decade University of Turin research on hepatocyte growth factor (HGF) for tissue regeneration formed the scientific foundation on which AgomAb Therapeutics was built.
Tim Knotnerus (Netherlands · ♂) — He supported AgomAb from 2017 and joined as CEO in early 2019, leading the company that commercializes Michieli's regenerative-antibody science.

Date	Round	Amount
Oct 2023	Series C Belgian biotech AgomAb Therapeutics raised a $100M Series C led by Fidelity to combat fibrosis.	$100M

Tap an investor to see what else they have backed.

Data is community-curated and may be incomplete.